Ian F. Walker

Ian F. Walker

Auto-generated profile, based on publicly available information

Ian F. Walker

Nuffield Centre for International Health and Development, University of Leeds, Leeds, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Value in Health Regional Issues
Verified
Journal Article
Closed access
IWIan F. Walker
Ian F. Walker
FGFredrike Garbe
Fredrike Garbe
JWJudy Wright
Judy Wright
INIan Newell
Ian Newell
NANaveen Athiraman
Naveen Athiraman
HEHelen Elsey
Helen Elsey

9 May 2019 in European Respiratory Journal
Verified
Journal Article
Closed access
IWIan F. Walker
Ian F. Walker
OSOumin Shi
Oumin Shi
JHJoseph P. Hicks
Joseph P. Hicks
HEHelen Elsey
Helen Elsey
Xiaolin WeiXiaolin Wei
Xiaolin Wei
JNJames N. Newell
James N. Newell
Loss to follow-up (LFU) of ≥2 consecutive months contributes to the poor levels of treatment success in multidrug-resistant tuberculosis (MDR-TB) reported by TB programmes. We explored the timing of when LFU occurs by month of MDR-TB treatment and identified patient-level risk factors associated with LFU.We analysed a dataset of individual MDR-TB patient data (4099 patients from 22 countries). We used Kaplan–Meier survival curves to plot time to LFU and a Cox proportional hazards model to explore the association of potential risk factors with LFU.Around one-sixth (n=702) of patients were recorded as LFU. Median (interquartile range) time to LFU was 7 (3–11) months. The majority of LFU occurred in the initial phase of treatment (75% in the first 11 months). Major risk factors associated with LFU were: age 36–50 years (HR 1.3, 95% CI 1.0–1.6; p=0.04) compared with age 0–25 years, being HIV positive (HR 1.8, 95% CI 1.2–2.7; p<0.01) compared with HIV negative, on an individualised treatment regimen (HR 0.7, 95% CI 0.6–1.0; p=0.03) compared with a standardised regimen and a recorded serious adverse event (HR 0.5, 95% CI 0.4–0.6; p<0.01) compared with no serious adverse event.Both patient- and regimen-related factors were associated with LFU, which may guide interventions to improve treatment adherence, particularly in the first 11 months.

26 July 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
IWIan F Walker
Ian F Walker
SKSudeepa Khanal
Sudeepa Khanal
JHJoe P Hicks
Joe P Hicks
BLBikash Lamichhane
Bikash Lamichhane
ATAnil Thapa
Anil Thapa
JNJames N Newell
James N Newell
People receiving treatment for multidrug-resistant tuberculosis (MDR-TB) have high rates of depression. Psychosocial support in general, and treatments for depression in particular, form an important but neglected area of patient-centred care, and a key pillar in the global End TB strategy. We assessed the feasibility and acceptability of a psychosocial support package for people receiving treatment for MDR-TB in Nepal. This feasibility study used a mixed quantitative and qualitative approach. We implemented the intervention package in two National Tuberculosis Programme (NTP) MDR-TB treatment centres and 8 sub-centres. We screened patients monthly for depression and anxiety (cut-off ≥24 and ≥17 respectively on the Hopkins Symptom Checklist) and also for low social support (cut-off ≤3 on the Multidimensional Scale of Perceived Social Support). Those who screened positive on either screening tool received the Healthy Activity Program (HAP), which uses brief counselling based on behavioural activation theory. Other aspects of the psychosocial package were information/education materials and group interactions with other patients. We screened 135 patients, of whom 12 (9%) received HAP counselling, 115 (85%) received information materials, 80 (59%) received an education session and 49 (36%) received at least one group session. Eight group sessions were conducted in total. All aspects of the intervention package were acceptable to patients, including the screening, information, group work and counselling. Patients particularly valued having someone to talk to about their concerns and worries. We were able to successfully train individuals with no experience of psychological counselling to deliver HAP. This psychosocial support package is acceptable to patients. The information materials we developed are feasible to deliver in the current NTP. However, the structured psychological counselling (HAP), is not feasible in the current NTP due to time constraints. This requires additional investment of counsellors in TB clinics.

1 July 2018 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
IWI F Walker
I F Walker
AKAhmar M Khan
Ahmar M Khan
AKAmir M Khan
Amir M Khan
NKN M Khan
N M Khan
RAR M Ayub
R M Ayub
JWJohn Deric Walley
John Deric Walley
BACKGROUND AND OBJECTIVES: Depression is likely to be a factor in the low global rates of successful treatment for multidrug-resistant tuberculosis (MDR-TB) due to poor adherence to treatment. We aimed to estimate the prevalence of depression among patients being treated for MDR-TB in Pakistan, explore rates of depression over the course of treatment and identify risk factors for depression. DESIGN: This cross-sectional study analysed health care service data from 12 treatment sites following a single screening event using the Patient Health Questionnaire 9 (PHQ-9). Logistic regression models were used to identify associations. RESULTS: Data were collected from 1279 patients with MDR-TB. The proportion of MDR-TB patients with depression was 42.8% (95%CI 40.1–45.5). Rates of depression varied according to duration of treatment, with the highest proportion (53.2%) found in those who were in months 10–12 of treatment. The odds of depression in women were higher than for men (adjusted odds ratio [aOR] 1.84, 95%CI 1.46–2.33). The odds of depression were higher in patients living in concrete-built houses than in those living in mud-built houses (aOR 1.37, 95%CI 1.03–1.82). CONCLUSION: Depression is common in MDR-TB patients, and should be screened for and treated within MDR-TB treatment programmes.

1 June 2017 in The International Journal of Tuberculosis and Lung Disease
Verified
Journal Article
Closed access
IWI F Walker
I F Walker
SBS C Baral
S C Baral
XWX Wei
X Wei
RHR Huque
R Huque
AKA Khan
A Khan
HEHelen Elsey
Helen Elsey
The successful treatment of multidrug-resistant tuberculosis (MDR-TB) is a global health priority and a key pillar of the World Health Organization's (WHO's) End TB strategy. There has been significant global investment in diagnostic capabilities in recent years. However, we argue that the mental distress of those with MDR-TB and their families continues to be overlooked by TB programmes. Priorities in the End TB Strategy of ‘patient-centred care' and ‘patient support' are still to be delivered in practice in many low-income settings, and in particular consideration of mental distress. Our experience of undertaking MDR-TB operational research in China, Pakistan, Bangladesh, Nepal and Swaziland has given us detailed insight into the challenges facing patients, their families, health professionals and wider health systems. We are increasingly concerned that psychosocial support, and particularly support focused on mental health, is being insufficiently addressed in national MDR-TB programmes. We suggest that the presence of comorbid mental disorders reduces treatment adherence. We recommend the trialling within TB programmes of brief screening tools for common mental disorders and the incorporation of principles from the WHO Mental Health Gap Action Programme programme into TB programme treatment guidance. Our work in Nepal also suggests that brief psychological counselling delivered by non-specialist counsellors may be feasible.

1 March 2019 in Public Health Action
Verified
Journal Article
Closed access
IWI. F. Walker
I. F. Walker
SKS. Kanal
S. Kanal
SBS. C. Baral
S. C. Baral
TFTracey Farragher
Tracey Farragher
DJD. Joshi
D. Joshi
JNJ. N. Newell
J. N. Newell
Setting: Multidrug-resistant tuberculosis (MDR-TB) patients in the national TB treatment programme of Nepal. Objective: To estimate the prevalence of depression and anxiety in people receiving treatment for MDR-TB, identify potential risk factors for depression and anxiety and determine temporal changes in their severity during treatment. Design: An observational study using a screening tool, the Hopkins Symptom Checklist (HSCL-25) for depression and anxiety, administered monthly to a group of 135 patients in Nepal. Logistic and multilevel linear regression models were used to identify any patient characteristics associated with depression and anxiety. Results: Most of the 135 patients were male (76%) and living with their families (68%). The period prevalences of depression and anxiety were respectively 22.2% and 15.6%. Patients reporting physical side effects of MDR-TB treatment had a higher depression score on HSCL by 2.63 points (95%CI 0.77–4.48) and a 1.59 point higher anxiety score (95%CI 0.45–2.73) than those who did not report any side effects. Being single was associated with having anxiety (aOR 0.2, 95%CI 0.03–1.0). Conclusion: Given the high rates of depression observed among MDR-TB patients, national TB treatment programmes should ensure their patients are routinely screened for depression and anxiety, and effective treatment offered.